Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease

NCT04330326 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-02-10

No results posted yet for this study

Summary

This short-term, randomized, placebo-controlled, investigator-initiated trial aims to establish metabolic improvements in NAFLD subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside and serine. Concomitant use of pivotal metabolic cofactors via simultaneous dietary supplementation will stimulate three different pathways to enhance hepatic β-oxidation and this study's hypothesis is that this will result in decreased amount of fat in the liver.

Conditions

  • Non-alcoholic Fatty Liver Disease (NAFLD)

Interventions

DRUG

Metabolic Cofactor Supplementation

Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).

DRUG

Sorbitol

As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).

Sponsors & Collaborators

  • Koç University

    collaborator OTHER
  • Koç University Hospital

    collaborator UNKNOWN
  • Göteborg University

    collaborator OTHER
  • Sahlgrenska University Hospital

    collaborator OTHER
  • KTH Royal Institute of Technology

    collaborator OTHER
  • University of Helsinki

    collaborator OTHER
  • Helsinki University Central Hospital

    collaborator OTHER
  • Monitor CRO

    collaborator INDUSTRY
  • ScandiBio Therapeutics AB

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-20
Primary Completion
2020-07-29
Completion
2022-05-06

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04330326 on ClinicalTrials.gov